T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy
Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limited. Here, we prospectively measured the percentages of 15 circulating T-cell subtypes using flow cytometry. We obtained transversal and longitudinal data in 30 anti-TNF responders, 19 secondary anti-T...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2017/6894374 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568324476633088 |
|---|---|
| author | Sonja Dulic Zsófia Vásárhelyi Florentina Sava László Berta Balázs Szalay Gergely Toldi László Kovács Attila Balog |
| author_facet | Sonja Dulic Zsófia Vásárhelyi Florentina Sava László Berta Balázs Szalay Gergely Toldi László Kovács Attila Balog |
| author_sort | Sonja Dulic |
| collection | DOAJ |
| description | Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limited. Here, we prospectively measured the percentages of 15 circulating T-cell subtypes using flow cytometry. We obtained transversal and longitudinal data in 30 anti-TNF responders, 19 secondary anti-TNF nonresponders, and 43 IL-6R antagonist responders, before, 8 weeks and at least 6 months after biological therapy. Untreated RA patients and healthy controls were also included. The important findings are the following: (1) the proportion of regulatory T-cells (Tregs) which are decreased in untreated RA patients becomes normal in all long-term-treated groups; (2) in anti-TNF responders as well as in nonresponders, the frequencies of naïve CD4+ and CD8+ cells are lower, whereas those of proinflammatory Th1, Th2, and Th17 cells and HLA-DR+-activated cells are higher than those in untreated RA or healthy controls; (3) in IL-6R responders, Th1 proportion is decreased, while that of Th2 and Th17 is increased as compared to that in anti-TNF-treated patients and controls; (4) pending confirmation, a CD4CD69 ratio < 2.43 at baseline, could be useful to predict a good therapeutic response to anti-TNF therapy. This study provides comprehensive information regarding the long-term impacts of those biological therapies on the ecotaxis of T-cells in RA. The ClinicalTrials.gov registration number of our study is NCT03266822. |
| format | Article |
| id | doaj-art-e96668bf91bc41848387cc1802e4909a |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-e96668bf91bc41848387cc1802e4909a2025-02-03T00:59:25ZengWileyMediators of Inflammation0962-93511466-18612017-01-01201710.1155/2017/68943746894374T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker TherapySonja Dulic0Zsófia Vásárhelyi1Florentina Sava2László Berta3Balázs Szalay4Gergely Toldi5László Kovács6Attila Balog7Department of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, HungaryFirst Department of Obstetrics and Gynecology, Semmelweis University, Budapest, HungaryFirst Department of Obstetrics and Gynecology, Semmelweis University, Budapest, HungaryFirst Department of Pediatrics, Semmelweis University, Budapest, HungaryDepartment of Laboratory Medicine, Semmelweis University, Budapest, HungaryFirst Department of Obstetrics and Gynecology, Semmelweis University, Budapest, HungaryDepartment of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, HungaryDepartment of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, HungaryData on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limited. Here, we prospectively measured the percentages of 15 circulating T-cell subtypes using flow cytometry. We obtained transversal and longitudinal data in 30 anti-TNF responders, 19 secondary anti-TNF nonresponders, and 43 IL-6R antagonist responders, before, 8 weeks and at least 6 months after biological therapy. Untreated RA patients and healthy controls were also included. The important findings are the following: (1) the proportion of regulatory T-cells (Tregs) which are decreased in untreated RA patients becomes normal in all long-term-treated groups; (2) in anti-TNF responders as well as in nonresponders, the frequencies of naïve CD4+ and CD8+ cells are lower, whereas those of proinflammatory Th1, Th2, and Th17 cells and HLA-DR+-activated cells are higher than those in untreated RA or healthy controls; (3) in IL-6R responders, Th1 proportion is decreased, while that of Th2 and Th17 is increased as compared to that in anti-TNF-treated patients and controls; (4) pending confirmation, a CD4CD69 ratio < 2.43 at baseline, could be useful to predict a good therapeutic response to anti-TNF therapy. This study provides comprehensive information regarding the long-term impacts of those biological therapies on the ecotaxis of T-cells in RA. The ClinicalTrials.gov registration number of our study is NCT03266822.http://dx.doi.org/10.1155/2017/6894374 |
| spellingShingle | Sonja Dulic Zsófia Vásárhelyi Florentina Sava László Berta Balázs Szalay Gergely Toldi László Kovács Attila Balog T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy Mediators of Inflammation |
| title | T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy |
| title_full | T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy |
| title_fullStr | T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy |
| title_full_unstemmed | T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy |
| title_short | T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy |
| title_sort | t cell subsets in rheumatoid arthritis patients on long term anti tnf or il 6 receptor blocker therapy |
| url | http://dx.doi.org/10.1155/2017/6894374 |
| work_keys_str_mv | AT sonjadulic tcellsubsetsinrheumatoidarthritispatientsonlongtermantitnforil6receptorblockertherapy AT zsofiavasarhelyi tcellsubsetsinrheumatoidarthritispatientsonlongtermantitnforil6receptorblockertherapy AT florentinasava tcellsubsetsinrheumatoidarthritispatientsonlongtermantitnforil6receptorblockertherapy AT laszloberta tcellsubsetsinrheumatoidarthritispatientsonlongtermantitnforil6receptorblockertherapy AT balazsszalay tcellsubsetsinrheumatoidarthritispatientsonlongtermantitnforil6receptorblockertherapy AT gergelytoldi tcellsubsetsinrheumatoidarthritispatientsonlongtermantitnforil6receptorblockertherapy AT laszlokovacs tcellsubsetsinrheumatoidarthritispatientsonlongtermantitnforil6receptorblockertherapy AT attilabalog tcellsubsetsinrheumatoidarthritispatientsonlongtermantitnforil6receptorblockertherapy |